Akari Therapeutics, Plc (NASDAQ:AKTX – Get Free Report) was the recipient of a significant decline in short interest during the month of August. As of August 15th, there was short interest totalling 10,500 shares, a decline of 95.7% from the July 31st total of 243,800 shares. Based on an average trading volume of 31,400 shares, the short-interest ratio is presently 0.3 days. Approximately 0.3% of the shares of the company are sold short.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in AKTX. Renaissance Technologies LLC grew its position in Akari Therapeutics by 411.4% during the first quarter. Renaissance Technologies LLC now owns 283,550 shares of the biopharmaceutical company’s stock worth $52,000 after buying an additional 228,100 shares during the period. Cerity Partners LLC acquired a new stake in shares of Akari Therapeutics in the second quarter valued at approximately $55,000. LPL Financial LLC acquired a new stake in shares of Akari Therapeutics in the second quarter valued at approximately $83,000. Finally, Sabby Management LLC grew its position in shares of Akari Therapeutics by 116.5% in the first quarter. Sabby Management LLC now owns 7,941,867 shares of the biopharmaceutical company’s stock valued at $1,443,000 after purchasing an additional 4,273,528 shares during the last quarter. 13.60% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Separately, StockNews.com started coverage on shares of Akari Therapeutics in a report on Sunday, August 20th. They issued a “sell” rating for the company.
Akari Therapeutics Stock Up 3.5 %
NASDAQ AKTX opened at $3.55 on Friday. The stock has a market capitalization of $13.21 million, a P/E ratio of -0.51 and a beta of 1.34. Akari Therapeutics has a 52-week low of $2.81 and a 52-week high of $25.40. The firm has a 50-day moving average price of $3.85 and a 200 day moving average price of $4.51.
About Akari Therapeutics
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.
Read More
- Five stocks we like better than Akari Therapeutics
- What Are Meme Stocks and Are They Viable Investments?
- One of these 5 Pet Care Stocks Can Be the Next Short Squeeze
- Insider Buying Explained: What Investors Need to Know
- 3 High Short Interest Stocks that Investors are Getting Wrong
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Retail Theft Rises: Two Ways For Investors To Beat Shrinkage
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
